Inaugural Rare Disease Patient Advocacy Guidelines Published

Thursday, February 15, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

PHILADELPHIA, Feb. 14, 2018 /PRNewswire/ -- Susan Stein, MPH, CEO and Founder of the award-winning Connexion Healthcare,

has announced the open-access publication of rare disease patient advocacy guidelines for interaction with biopharmaceutical companies, the first publication of its kind. Affecting approximately 350 million people, rare diseases are now a global public
health concern. As head of the first and only healthcare communications agency dedicated solely to oncology and rare diseases, Stein identified an unmet need where patient advocates and biopharmaceutical companies interact for the development of novel therapies. "We convened an independent panel to explore consensus guidelines and the Connexion team developed a poster that was accepted and presented at the 2017 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit," said Stein. The interest and response was eye opening, resulting in submission and publication of the output in the Orphanet Journal of Rare Diseases. Representatives from Connexion Healthcare, Global Genes, REGENXBIO, Spark Therapeutics, Akcea Therapeutics, the Friedreich's Ataxia Research Alliance (FARA), the Research Committee of the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), the National Tay-Sachs & Allied Diseases Association (NTSAD), and Niemann-Pick UK were authors on the publication. "Patient advocacy organizations now have free and shareable access to guidelines for clarity in day to day decision making. Our hope is that this remains a living document, updated and revised regularly in collaboration with the patient advocacy community. It is a true testament to our patient centric commitment at Connexion Healthcare to promote change for those afflicted with a rare disease," Stein added.

About the Guidelines

Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases, can be found at https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0761-2 or request a copy at info@connexionhealthcare.com

About Connexion Healthcare

Connexion Healthcare is an award-winning, full-service thought leader engagement and education agency founded in 1999. Connexion is focused on educating healthcare professionals, advocates, patients and caregivers by providing accurate and clear scientific exchanges, and combining our dedication to scientific excellence with a thorough understanding of business objectives and strategies. Connexion is a certified woman-owned business and member of the Women's Business Enterprise National Council (WBENC), with main offices located in Philadelphia, PA. We invite you to visit our website at connexionhealthcare.com and tweet us @ConnexionHC.

CONTACT:  Susan Stein, MPH  CEO, Connexion Healthcare  Phone: 215.944.9405  Email: sstein@connexionhealthcare.com  Twitter: @CONNEXIONhealth

Cision View original content:http://www.prnewswire.com/news-releases/inaugural-rare-disease-patient-advocacy-guidelines-published-300598865.html

SOURCE Connexion Healthcare

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store